Comparative Pharmacology
Head-to-head clinical analysis: ATHENTIA NEXT versus BLISOVI 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATHENTIA NEXT versus BLISOVI 24 FE.
ATHENTIA NEXT vs BLISOVI 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that inhibits ovulation and alters cervical mucus, reducing sperm penetration. Ethinyl estradiol suppresses gonadotropin release, preventing follicular development.
Combination of ethinyl estradiol and drospirenone; primarily suppresses gonadotropins (FSH, LH) via negative feedback, preventing ovulation. Drospirenone has anti-mineralocorticoid and anti-androgenic activity.
Not established. ATHENTIA NEXT is not a recognized pharmaceutical agent. Consult official prescribing information.
One tablet orally once daily for 24 weeks, followed by placebo tablets for 4 weeks; each tablet contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol for 21 days, then 0.01 mg ethinyl estradiol for 3 days, then 2 tablets of 75 mg ferrous fumarate for 5 days.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in healthy adults; clinically relevant for once-daily dosing.
Drospirenone: 25-33 hours; Ethinyl estradiol: 13-24 hours; steady-state achieved after 10 days.
Renal excretion of unchanged drug: 60-70%; fecal/biliary elimination: 20-30%; hepatic metabolism accounts for <10%.
Renal: 30-40% as drospirenone metabolites, 20-30% as ethinyl estradiol metabolites; fecal: 40-50% as drospirenone metabolites, 30-40% as ethinyl estradiol metabolites; biliary: minimal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive